220 related articles for article (PubMed ID: 10832449)
21. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
Body JJ; Louviaux I; Dumon JC
Support Care Cancer; 2000 Sep; 8(5):398-404. PubMed ID: 10975689
[TBL] [Abstract][Full Text] [Related]
22. Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions.
Culbert EC; Schfirin BS
Obstet Gynecol; 2006 Sep; 108(3 Pt 2):789-91. PubMed ID: 17018504
[TBL] [Abstract][Full Text] [Related]
23. [A case of multiple bone metastases from advanced breast cancer effectively treated with pamidronate].
Nakaguchi K; Furukawa J; Shingai T; Azama T; Yoshioka S; Katsumoto Y; Morimoto T; Okajima S; Sue F
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1465-7. PubMed ID: 10500535
[TBL] [Abstract][Full Text] [Related]
24. [Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma].
Kise H; Kobayashi K; Arima K; Yanagawa M; Tochigi H; Kawamura J; Hioki T; Sugiura Y
Hinyokika Kiyo; 1996 Nov; 42(11):879-81. PubMed ID: 8973939
[TBL] [Abstract][Full Text] [Related]
25. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
26. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial.
Conte PF; Giannessi PG; Latreille J; Mauriac L; Koliren L; Calabresi F; Ford JM
Ann Oncol; 1994; 5 Suppl 7():S41-4. PubMed ID: 7873461
[TBL] [Abstract][Full Text] [Related]
27. A remarkable improvement of clinical manifestations in a breast cancer patient with widespread bone metastases after administration of pamidronate.
Kage K; Nagahama T; Sekine I; Maruyama M; Ogata E
Intern Med; 1997 Dec; 36(12):926-30. PubMed ID: 9475253
[TBL] [Abstract][Full Text] [Related]
28. Hypercalcemia and bone metastases in breast cancer.
Warrell RP
Curr Opin Oncol; 1990 Dec; 2(6):1097-103. PubMed ID: 2151596
[No Abstract] [Full Text] [Related]
29. Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy.
Binstock ML; Mundy GR
Ann Intern Med; 1980 Aug; 93(2):269-72. PubMed ID: 7406378
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
31. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy.
Jung A
Am J Med; 1982 Feb; 72(2):221-6. PubMed ID: 6460442
[TBL] [Abstract][Full Text] [Related]
32. Quality and Outcomes of Treatment of Hypercalcemia of Malignancy.
Wright JD; Tergas AI; Ananth CV; Burke WM; Hou JY; Chen L; Neugut AI; Richards CA; Hershman DL
Cancer Invest; 2015; 33(8):331-9. PubMed ID: 26068056
[TBL] [Abstract][Full Text] [Related]
33. Parenteral diphosphonates for treating malignant hypercalcemia.
Jung A; van Ouwenaller C; Chantraine A; Courvoisier B
Cancer; 1981 Oct; 48(8):1922-5. PubMed ID: 6456809
[TBL] [Abstract][Full Text] [Related]
34. Hypercalcemia and status epilepticus relates to salmon calcitonin administration in breast cancer.
Chung SY; Chen TH; Lai SL; Huang CH; Chen WH
Breast; 2005 Oct; 14(5):399-402. PubMed ID: 16143533
[TBL] [Abstract][Full Text] [Related]
35. Zoledronic acid. A bisphosphonate for hypercalcemia of malignancy and osteolytic metastases.
Massaro AM
Cancer Pract; 2002; 10(4):219-21. PubMed ID: 12100107
[No Abstract] [Full Text] [Related]
36. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
Tubiana-Hulin M; de Vernejoul MC; Brière M; Miravet L; Clavel B
Presse Med; 1984 Feb; 13(8):483-6. PubMed ID: 6230630
[TBL] [Abstract][Full Text] [Related]
37. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
Yates AJ; Murray RM; Jerums GJ; Martin TJ
Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316
[TBL] [Abstract][Full Text] [Related]
38. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
Tai N; Inoue D
Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
[TBL] [Abstract][Full Text] [Related]
39. A case of myeloma with hypercalcemia caused by high serum concentrations of both parathyroid hormone-related peptide (PTHrP) and macrophage inflammatory protein-1α (MIP-1α).
Shimizu H; Monden T; Tomotsune T; Nakatani Y; Domeki N; Matsumura M; Jojima T; Kawagoe Y; Kasai K
Intern Med; 2011; 50(24):2993-6. PubMed ID: 22185991
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
Coleman RE
Oncology (Williston Park); 1991 Aug; 5(8):55-60; discussion 60-2, 65. PubMed ID: 1834153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
